REVERSING PRE-DABETES USING FUSION PROTEINS COMPRISING A GAD PEPTIDE

Johnson, G.G., et al. J. Immunol. 1999; 163:5678-5685.* Pozzilli, P., et al. Diabetol. 2000:43:1000-1004.* Goodnow, C.C. The Lancet. 2001:357:2115-2121.* Kraus, T.A., and Mayer, L. Curr. Opin. Gastroenterol. 2005:21:692 696. Bell, J.J. et al. J. Immunol. 2008; 180: 1508-1516. Haller, M.J., et al. Eur, J. Immunol. 2009:39:2054-2058/.* von Herrath, M. and Nepom, G.T. Nature Immunol. 2009; 10(2): 129 132.* Leslie, M. Science. 2009:327: 1573.* van der Worp, H.B., et al. PLoS Med. 2010;7(3): 1-8.* Petersen, J.S., et al. Autoimmunity. 1997:25:129-138. Hanlon, S.B., et al. Autoimmunity. 1999:31:15-24.* Couzin, J. “Diabetes’ Brave New World.” Science. 2003; 300: 1862 1865. Harrison, L. “Vaccination Against Self to Prevent Autoimmune Dis ease: The Type 1 Diabetes Model.” Immunology and Cell Biology. 2008; 86: 139-145. Liu, C. "Detection of Glutamic Acid Decarboxylase-Activated T cells with I-Ag7 Tetramers.” PNAS. 2000:97(26): 14596-14601. Marketletter, "AutoImmune Shares Collapse on Coloral Data in Rheumatoid Arthritis.” Sep. 13, 1999, Marketletter Publications Ltd. Anderton, Stephen M.. “Peptide-Based Immunotherapy of Autoim munity: A Path of Puzzles, Paradoxes and Possibilities.” Immunol ogy 2001; 104: 367-376. Legge, Kevin L., et al., “TCRAgonist and Antagonist Exert In Vivo Cross-Regulation When Presented on Igs.” J. Immunology 1998; 161: 106-111. Dong, VM, et al., “Transplantation Tolerance: The Concept and Its Applicability.” Ped. Transplan. 1999; 3 181-192. Balasa, B., et al., “A Mechanism for IL-10-Mediated Diabetes in the Nonobese Diabetic (NOD) Mouse: ICAM-1 Deficiency Blocks Accelerated Diabetes.” The Journal of Immunology, vol. 165, pp. 7330-7337 (2000). Bu, Ding-Fang, et al., “Two Human Glutamate Decarboxylases, 65-kDa GAD and 67-kDa GAD, Are Each Encoded by a Single Gene.” Proc. Natl. Acad. Sci. USA, vol. 89, pp. 2115-2119 (1992). Gregg, Randal, et al., “IL-10 Diminishes CTLA-4 Expression on Islet-Resident T Cells and Sustains Their Activation Rather Than Tolerance.” The Journal of Immunology, vol. 174, pp. 662-670 (2005). Gregg, Randal, et al., “A Sudden Decline in Active Membrane-Bound TGF-B Impairs Both T Regulatory Cell Function and Protection Against Autoimmune Diabetes. The Journal of Immunology, vol. 173, pp. 7308-7316 (2004). Kaufman, D., et al., “Autoimmunity to Two Forms of Glutamate Decarboxylase in Insulin-Dependent Diabetes Mellitus,” Journal of Clinical Investigation, vol. 89, pp. 283-292 (1992). Legge, K., et al., “Coupling of Peripheral Tolerance to Endogenous Interleukin 10 Promotes Effective Modulation of Myelin-Activated T Cells and Ameliorates Experimental Allergic Encephalomyelitis,” J. Exp. Med., vol. 191, No. 12, pp. 2039-2051 (2000). Legge, K., et al., “Multi-Modal Antigen Specific Therapy for Autoimmunity.” Intern. Rev. Immunol., vol. 20, pp. 593-611 (2001). Zambidis, E., et al., “Epitope-Specific Tolerance Induction with an Engineered Immunoglobulin.” Proc. Natl. Acad. Sci. USA. Immu nology, vol. 93, pp. 5019-5024 (1996).

[1]  K. Legge,et al.  On the Role of Dendritic Cells in Peripheral T Cell Tolerance and Modulation of Autoimmunity , 2002, The Journal of experimental medicine.

[2]  D. Wegmann,et al.  Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. , 2002, Diabetes.

[3]  Meng Chen,et al.  Suppression of Autoimmune Diabetes by Viral IL-10 Gene Transfer1 , 2002, The Journal of Immunology.

[4]  David F. Richards,et al.  In Vitro Generation of Interleukin 10–producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)– and Th2-inducing Cytokines , 2002, The Journal of experimental medicine.

[5]  A. Cooke,et al.  Cutting Edge: Interactions Through the IL-10 Receptor Regulate Autoimmune Diabetes1 , 2001, The Journal of Immunology.

[6]  E. Bonifacio,et al.  International Workshop on Lessons From Animal Models for Human Type 1 Diabetes: identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice. , 2001, Diabetes.

[7]  M. Roncarolo,et al.  Type 1 T regulatory cells , 2001, Immunological reviews.

[8]  R. Flavell,et al.  A Dual Role for TNF-α in Type 1 Diabetes: Islet-Specific Expression Abrogates the Ongoing Autoimmune Process When Induced Late but Not Early During Pathogenesis1 , 2001, The Journal of Immunology.

[9]  W. Suarez-Pinzon,et al.  Th1 to Th2 Cytokine Shifts in Nonobese Diabetic Mice: Sometimes an Outcome, Rather Than the Cause, of Diabetes Resistance Elicited by Immunostimulation1 , 2001, The Journal of Immunology.

[10]  K. Legge,et al.  Multi-Modal Antigen Specific Therapy for Autoimmunity , 2001, International reviews of immunology.

[11]  Asaf Rotem,et al.  Vaccination with Empty Plasmid DNA or CpG Oligonucleotide Inhibits Diabetes in Nonobese Diabetic Mice: Modulation of Spontaneous 60-kDa Heat Shock Protein Autoimmunity1 , 2000, The Journal of Immunology.

[12]  K. Legge,et al.  Coupling of Peripheral Tolerance to Endogenous Interleukin 10 Promotes Effective Modulation of Myelin-Activated T Cells and Ameliorates Experimental Allergic Encephalomyelitis , 2000, The Journal of experimental medicine.

[13]  E. Unanue,et al.  Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II molecule of NOD mice. , 2000, Immunity.

[14]  M. Rewers,et al.  Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Cooke,et al.  Peptides derived from murine insulin are diabetogenic in both rats and mice, but the disease-inducing epitopes are different: evidence against a common environmental cross-reactivity in the pathogenicity of type 1 diabetes. , 1999, Diabetes.

[16]  H. Y. Song,et al.  Human insulin B chain but not A chain decreases the rate of diabetes in BB rats. , 1999, Diabetes research and clinical practice.

[17]  Fiona Powrie,et al.  An Essential Role for Interleukin 10 in the Function of Regulatory T Cells That Inhibit Intestinal Inflammation , 1999, The Journal of experimental medicine.

[18]  P. Nickerson,et al.  IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. , 1999, Journal of immunology.

[19]  K. Legge,et al.  Neonatal Exposure to a Self-Peptide–Immunoglobulin Chimera Circumvents the Use of Adjuvant and Confers Resistance to Autoimmune Disease by a Novel Mechanism Involving Interleukin 4 Lymph Node Deviation and Interferon γ–mediated Splenic Anergy , 1998, The Journal of experimental medicine.

[20]  Jonathan M. Austyn,et al.  Dendritic cells , 1998, Current opinion in hematology.

[21]  C. Benoist,et al.  Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Bhagirath Singh,et al.  The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. , 1997, Immunity.

[23]  P. Nickerson,et al.  A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. , 1997, Journal of immunology.

[24]  K. Legge,et al.  Presentation of a T Cell Receptor Antagonist Peptide by Immunoglobulins Ablates Activation of  T Cells by a Synthetic Peptide or Proteins Requiring Endocytic Processing , 1997, The Journal of experimental medicine.

[25]  N. Sarvetnick,et al.  IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity , 1996, The Journal of experimental medicine.

[26]  D. Scott,et al.  Epitope-specific tolerance induction with an engineered immunoglobulin. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Tisch,et al.  Insulin-Dependent Diabetes Mellitus , 1996, Cell.

[28]  N. Sarvetnick,et al.  The paradoxical effects of interleukin 10 in the immunoregulation of autoimmune diabetes. , 1996, Journal of autoimmunity.

[29]  C. Benoist,et al.  Checkpoints in the progression of autoimmune disease: lessons from diabetes models. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Wegmann,et al.  Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  F. Lepault,et al.  Isolation of leukocytes infiltrating the islets of Langerhans of diabetes-prone mice for flow cytometric analysis. , 1995, Journal of immunological methods.

[32]  D. Wegmann,et al.  Insulin‐specific T cells are a predominant component of islet infiltrates in pre‐diabetic NOD mice , 1994, European journal of immunology.

[33]  J. Bach,et al.  Insulin-dependent diabetes mellitus as an autoimmune disease. , 1994, Endocrine reviews.

[34]  M. Monahan,et al.  Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. , 1994, Clinical immunology and immunopathology.

[35]  N. Sarvetnick,et al.  Production of interleukin 10 by islet cells accelerates immune-mediated destruction of beta cells in nonobese diabetic mice , 1994, The Journal of experimental medicine.

[36]  R. Steinman,et al.  Efficient loading of identical viral peptide onto class II molecules by antigenized immunoglobulin and influenza virus , 1993, The Journal of experimental medicine.

[37]  R. Steinman,et al.  Presentation of a viral T cell epitope expressed in the CDR3 region of a self immunoglobulin molecule. , 1993, Science.

[38]  J. Feder,et al.  Thermal properties of human IgG. , 1987, Molecular immunology.

[39]  Y. Tochino,et al.  Breeding of a non-obese, diabetic strain of mice. , 1980, Jikken dobutsu. Experimental animals.

[40]  G. Eisenbarth,et al.  Insulin-specific tolerance in diabetes. , 2002, Clinical immunology.

[41]  A. Bot,et al.  Diabetic Mice Prevents Autoimmune Diabetes in Nonobese Plasmid Vaccination with Insulin B Chain , 2001 .

[42]  E. Shevach.  Regulatory T cells in autoimmmunity*. , 2000, Annual review of immunology.

[43]  K. Buschard,et al.  the Harwood Academic Publishers imprint, part of The Gordon and Breach Publishing Group. Printed in Malaysia. Neonatal Treatment with Beta-cell Stimulatory Agents Reduces the Incidence of Diabetes in BB Rats , 1999 .

[44]  H. Mcdevitt,et al.  Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. , 1995, Immunology today.

[45]  M. Erlander,et al.  Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. , 1992, The Journal of clinical investigation.

[46]  G. Eisenbarth,et al.  Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. , 1990, Annual review of immunology.

[47]  N. Sarvetnick,et al.  Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. , 1990, Nature.